加载中
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
收盘时
US$3.30
+US$0.12 · +3.77%
盘后
US$3.39
+US$0.09 · +2.73%
10月12日 17:13 ET
盘中时间采用ET。市场数据可能有所延迟。
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
日内区间
当前US$3.30
52周区间
当前US$3.30
盘中时间采用ET。市场数据可能有所延迟。
HeartSciences Inc. is a medical technology company dedicated to augmenting the clinical utility of electrocardiograms (ECGs) by integrating artificial intelligence (AI). The firm develops AI-enhanced ECG (AI-ECG) solutions, including an algorithm specifically designed to detect impaired cardiac relaxation or other forms of cardiac dysfunction, whether caused by heart disease or the natural aging process. Among its offerings is the MyoVista wavECG device, a 12-lead resting ECG that provides comprehensive diagnostic information concerning cardiac function alongside conventional ECG data in a single examination. Furthermore, the company offers MyoVista Insights, a cloud-based platform capable of hosting its AI-ECG algorithms across various ECG hardware systems. Established in 2007, HeartSciences Inc. operates from its headquarters in Southlake, Texas. The company was formerly named Heart Test Laboratories, Inc. until its rebranding to HeartSciences Inc. in October 2024.
日内区间
当前US$3.30
52周区间
当前US$3.30
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 4319 USD | 4350 USD | 1.86万 USD | 5150 USD | 1.44万 USD |
| 销货成本 | 13.31万 USD | 12.98万 USD | 10.12万 USD | 2.97万 USD | 3.45万 USD |
| 毛利 | −12.88万 USD | −12.55万 USD | −8.26万 USD | −2.46万 USD | −2.01万 USD |
| 研究与开发 | 28.39亿 USD | 438.61万 USD | 287.86万 USD | 246.09万 USD | 300.15万 USD |
| 销售、一般及管理费用 | 55.76亿 USD | 384.1万 USD | 334.46万 USD | 362.75万 USD | 168.78万 USD |
| 营业费用 | 828.41万 USD | 822.71万 USD | 622.32万 USD | 608.84万 USD | 468.93万 USD |
| 利息收入 | — | 8.78万 USD | — | — | — |
| 利息支出 | 75.3万 USD | 50.05万 USD | 35.41万 USD | 24.32万 USD | 37.16万 USD |
| 折旧和摊销 | 13.14万 USD | 12.8万 USD | 9.51万 USD | 13.55万 USD | 2.66万 USD |
| 营业利润 | −841.29万 USD | −835.26万 USD | −630.58万 USD | −611.3万 USD | −470.94万 USD |
| 净利润 | −914.19万 USD | −876.52万 USD | −660.52万 USD | −635.43万 USD | −482.83万 USD |
公司数据更新于 2026年10月12日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$3.00
下跌空间 9.09%评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年5月17日 | 1:100 | — | — |
已生效 2024年5月17日
1:100
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
